{Reference Type}: Journal Article
{Title}: Long-Term Medication Profiles in Parkinson's Disease under Subthalamic Deep Brain Stimulation: A Controlled Study.
{Author}: Theyer C;Beliveau V;Krismer F;Peball M;Mair K;Heim B;Djamshidian A;Kiechl S;Eisner W;Eschlböck S;Wenning GK;Willeit P;Seppi K;Poewe W;Mahlknecht P;
{Journal}: Mov Disord Clin Pract
{Volume}: 11
{Issue}: 7
{Year}: 2024 Jul 7
{Factor}: 4.514
{DOI}: 10.1002/mdc3.14065
{Abstract}: <B>BACKGROUND: </B>Subthalamic deep brain stimulation (STN-DBS) reduces antiparkinsonian medications in Parkinson's disease (PD) compared with the preoperative state. Longitudinal and comparative studies on this effect are lacking.<BR><B>OBJECTIVE: </B>To compare longitudinal trajectories of antiparkinsonian medication in STN-DBS treated patients to non-surgically treated control patients.<BR><B>METHODS: </B>We collected retrospective information on antiparkinsonian medication from PD patients that underwent subthalamic DBS between 1999 and 2010 and control PD patients similar in age at onset and baseline, sex-distribution, and comorbidities.<BR><B>RESULTS: </B>In 74 DBS patients levodopa-equivalent daily dose (LEDD) were reduced by 33.9-56.0% in relation to the preoperative baseline over the 14-year observational period. In 61 control patients LEDDs increased over approximately 10 years, causing a significant divergence between groups. The largest difference amongst single drug-classes was observed for dopamine agonists.<BR><B>CONCLUSIONS: </B>In PD patients, chronic STN-DBS was associated with a lower LEDD compared with control patients over 14 years.